Safety and activity of WX-0593 (Iruplinalkib) in patients with ALK- or ROS1-rearranged advanced non-small cell lung cancer: a phase 1 dose-escalation and dose-expansion trial
Yuankai Shi(Chinese Academy of Medical Sciences & Peking Union Medical College), Huaize Geng(Qilu Hospital of Shandong University), Helong Zhang(Shanghai International Studies University), Yi Hu(Union Hospital), Zhehai Wang(Shandong Tumor Hospital), Xuezhi Hao(Chinese Academy of Medical Sciences & Peking Union Medical College), Yanqiu Zhao(Henan Cancer Hospital), Yanping Hu(Chinese People's Liberation Army), Mingjing Ge(Luye Pharma (China)), Pei Lu(Shanghai Jiao Tong University), Jian Fang(Peking University), Weidong Li(Tianjin Medical University), Jianhua Chen(Xinjiang Medical University), Juan Li(Shandong University), Chunling Liu(Xinjiang Medical University), Jianan Huang(Soochow University), Jun Zhao(Beijing Institute of Technology), Kangsheng Gu(Anhui Medical University), Yiping Zhang(Zhejiang Cancer Hospital), Weiwei Ouyang(Guizhou Cancer Hospital), Shucai Zhang(Northeastern University), Jinlu Shan(Army Medical University), Wu Zhuang(Hunan University), Yan Yu(Binzhou Medical University), Yunpeng Liu(Shenyang Institute of Automation), Liangming Zhang(Yuhuangding Hospital), Xiaosheng Hang(Wuxi Fourth People's Hospital), Lin Wang(Shanxi Academy of Medical Sciences), Meimei Si
Cited by 35
Related Papers
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
|The Lancet Oncology|2011|4.1k
Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial
|The Lancet Oncology|2016|1.2k
Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction
|Journal of Clinical Oncology|2016|1k
Osimertinib with or without Chemotherapy in <i>EGFR</i> -Mutated Advanced NSCLC
|New England Journal of Medicine|2023|695